Evidence map›Paper›PMID 27040279›Full record

ArticleInternational journal of hematology2016

Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study.

Akira Morimoto, Yoko Shioda, Toshihiko Imamura, Kazuko Kudo, Hiroshi Kawaguchi, Kazuo Sakashita, Masahiro Yasui, Yuhki Koga, Ryoji Kobayashi, Eiichi Ishii and 5 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. [Clinical analysis of 72 children with Langerhans cell histiocytosis].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Langerhans cell histiocytosis of the skull in 23 children.European journal of medical research · 2024
    Article
  18. Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 13 institutions in 1 country.

Akira MorimotoDepartment of Pediatrics, Jichi Medical University of Medicine, 3311-1, Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. akira@jichi.ac.jp.
Yoko ShiodaPediatric Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Kazuko KudoDepartment of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.
Hiroshi KawaguchiDepartment of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
Kazuo SakashitaDivision of Hematology/Oncology, Nagano Children's Hospital, Azumino, Japan.
Masahiro YasuiDepartment of Hematology/Oncology, Osaka Medical Center and Research Institute for Maternal and Child Health, Izumi, Japan.
Yuhki KogaDepartment of Pediatrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Ryoji KobayashiDepartment of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.
Eiichi IshiiDepartment of Pediatrics, Ehime University Graduate School of Medicine, Toon, Japan.
Junichiro FujimotoNational Center for Child Health and Development, Tokyo, Japan.
Keizo HoribeClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Fumio BesshoDepartment of Pediatrics, Kyorin University School of Medicine, Tokyo, Japan.
Yukiko TsunematsuDepartment of Pediatrics and Adolescent Medicine, Juntendo University School of Medicine, Tokyo, Japan.
Shinsaku ImashukuDepartment of Laboratory Medicine, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan.
National Center For Child Health and Development · JPEhime University · JPFujita Health University · JPHiroshima University · JPJichi Medical University · JPJuntendo University · JPKyorin University · JPKyoto Prefectural University of Medicine · JPKyushu University · JPNagano Children's Hospital · JPNagoya Medical Center · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPSapporo Hokuyu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The JLSG-96 study reported very low mortality rates for children newly diagnosed with multifocal Langerhans cell histiocytosis (LCH). The JLSG-02 study was performed to further improve the prognosis from 2002 to 2009. The present study compared the therapeutic results of these two studies in terms of multisystem disease. All patients were treated with 6 weeks of the Induction A regimen, comprising cytarabine, vincristine and prednisolone, followed by maintenance therapy. Poor responders to Induction A were switched to Induction B. JLSG-02 has been revised from JLSG-96 in the following respects: prednisolone dosage during Induction A increased; duration of maintenance therapy extended from 24 to 48 weeks; cyclosporine introduced to Induction B for progressive disease. One hundred forty-seven children with multisystem LCH were evaluated. Of these, 84 were positive for risk of organ involvement (RO) and 63 were RO-negative. At the 6-week point, 76.2 % of RO+ and 93.7 % of RO- patients responded to Induction A. Five-year event-free survival (EFS) was 46.2 % [95 % confidence (CI), 35.5-56.9] for RO+ and 69.7 % (58.4-81.1) for RO-, which was significantly superior to that in JLSG-96 [26.8 % (13.3-40.4) and 38.9 % (16.4-61.4), respectively]. The intensified induction and prolonged maintenance regimens in JLSG-02 improved EFS in patients with multisystem LCH.

Indexed as

AdolescentChildChild, PreschoolClinical ProtocolsCyclosporineCytarabineDisease-Free SurvivalDrug Therapy, CombinationHistiocytosis, Langerhans-CellHumansMultiple Organ FailurePrednisoloneRemission InductionTime FactorsTreatment OutcomeVincristineCyclosporineCytarabinePrednisoloneVincristineChemotherapyClinical trialsLangerhans cell histiocytosis

Identifiers

PMID27040279
OpenAlexW2341514422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.